CN114601815A - Cannabidiol hard capsule and preparation method thereof - Google Patents
Cannabidiol hard capsule and preparation method thereof Download PDFInfo
- Publication number
- CN114601815A CN114601815A CN202011443195.9A CN202011443195A CN114601815A CN 114601815 A CN114601815 A CN 114601815A CN 202011443195 A CN202011443195 A CN 202011443195A CN 114601815 A CN114601815 A CN 114601815A
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- hard capsule
- dispersed particles
- acid
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
The invention provides a cannabidiol hard capsule which comprises a cannabidiol-containing composition, wherein the cannabidiol-containing composition comprises the following medicinal components in parts by weight: 50-73% of cannabidiol dispersed particles, 23-45% of a filling agent, 2-4.5% of a disintegrating agent and 0.5-2% of a lubricating agent. The cannabidiol hard capsule provided by the invention can improve the water solubility of cannabidiol, remarkably improve in-vitro dissolution, improve bioavailability, is convenient and safe to transport, carry, store and take, does not contain harmful and irritant components, and is suitable for industrial mass production and clinical application.
Description
Technical Field
The invention relates to the field of pharmacy, and in particular relates to a cannabidiol hard capsule and a preparation method thereof.
Background
Cannabidiol (CBD) is a fat-soluble compound, insoluble in water, readily soluble in organic solvents, with a solubility of 36mg/ml in ethanol and 60mg/ml in dimethyl sulfoxide. Cannabidiol has a melting point of about 66 ℃.
Cannabidiol is completely different from Tetrahydrocannabinol (THC), has no hallucinogenic effect, and has good pharmacological activity in the aspects of spasm, anxiety, depression, inflammation, cancer, virus resistance, pain relief, rheumatoid arthritis, multiple sclerosis, epilepsy, particularly intractable epilepsy and the like, so that cannabidiol becomes a hot spot of research in the global medical field. However, because of the inherent physicochemical properties of cannabidiol, the dissolution rate of cannabidiol in the form of an oral solid preparation is extremely low, which limits the development and clinical application of the oral solid preparation.
The prior cannabidiol related preparations are mostly solution, oral spray, suppository, suspension, freeze-dried powder and the like.
As in the currently marketed formulation products, the cannabidiol drug epididolex is approved by the FDA for the treatment of rare, severe pediatric epilepsy, namely Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex is an oral solution, which is inconvenient to transport, carry, store and take. In addition, the absolute ethyl alcohol is used in the prescription, so that the medicine cannot be taken by alcohol allergic patients, and the medicine is required to be taken for a long time, so that the health of children is damaged. Canada approved the compound drug, Sativex, containing cannabidiol and tetrahydrocannabinol for the treatment of multiple sclerosis. Because of the problems of difficult water solubility and low bioavailability of cannabidiol, Sativex is developed into a dosage form of oral spray and absorbed and administered through oral mucosa so as to solve the problem of administration through a gastrointestinal system. However, based on the information disclosed in Summary of product characteristics of Sativex, this design has not been found to solve these problems, and because of the difficulty in solving the solubility problem of cannabidiol in aqueous systems, the company has to choose the matrix of organic solvent system as the means of formulation formation, and finally choose absolute ethanol and propylene glycol as the solvents, which is an undesirable result well known to those skilled in the art, and the descriptions of Sativex also disclose the hazard of ethanol and the irritation caused by propylene glycol.
Patent CN107126414A discloses a cannabidiol liquid suspension for the treatment of arthritis which not only contains a large amount of preservatives, but is also inconvenient to transport, store and carry.
Patent CN110269843A discloses a cannabidiol nanoemulsion freeze-dried powder. Compared with oral preparations, the freeze-dried powder has the problems of inconvenient storage, transportation, carrying and use, and the administration route of the freeze-dried powder is muscle or vein and directly enters the blood circulation system. Compared with the oral administration process, the oral administration process is complex, exogenous substances (bacteria, insoluble particles and the like) are easily introduced, and the oral administration process directly enters the blood circulation of a human body and is easy to generate adverse reaction, so that potential safety hazards exist.
Aiming at the defects of cannabidiol preparation in the prior art, the cannabidiol preparation which is convenient and safe to transport, carry, store and take, avoids harmful and irritant components and has improved water solubility and the preparation method thereof are needed to be provided.
Disclosure of Invention
In order to overcome the defects of the cannabidiol preparation in the prior art, the invention aims to provide a cannabidiol hard capsule. The cannabidiol hard capsule can improve the water solubility of cannabidiol, remarkably improve in-vitro dissolution and improve bioavailability, is convenient and safe to transport, carry, store and take, does not contain harmful and irritant components, and is suitable for industrial mass production and clinical application.
The cannabidiol hard capsules of the invention comprise a cannabidiol-containing composition. The composition containing cannabidiol comprises the following medicinal components in parts by weight:
in the cannabidiol-containing composition of the invention, the cannabidiol dispersed particles comprise, by weight, 10% to 50% of cannabidiol, 50% to 88% of polyoxyethylene polyoxypropylene ether block copolymer, and 0.5% to 5% of antioxidant, preferably, the cannabidiol dispersed particles comprise, by weight, 10% to 30% of cannabidiol, 60% to 85% of polyoxyethylene polyoxypropylene ether block copolymer, and 1% to 4% of antioxidant.
In the cannabidiol-containing composition of the invention, the cannabidiol dispersed particles are spherical porous fluffy particles having a particle size D50 of 5 μm to 40 μm, preferably 5 μm to 30 μm, more preferably 5 μm to 20 μm, most preferably 5 μm to 15 μm.
In the cannabidiol-containing composition of the invention, the weight ratio (g/g) of cannabidiol to polyoxyethylene polyoxypropylene ether block copolymer in the cannabidiol dispersed particles is 1:8 to 1:1, preferably 1:5 to 1: 2.
In the cannabidiol-containing composition of the invention, the weight ratio (g/g) of cannabidiol to antioxidant in the cannabidiol dispersed particles is 20:1 to 5:1, preferably 16:1 to 7.5: 1.
In the cannabidiol-containing composition of the invention, the polyoxyethylene polyoxypropylene ether block copolymer in the cannabidiol dispersed particles is Poloxamer (Poloxamer)124, Poloxamer188, Poloxamer237, Poloxamer338, Poloxamer407, etc., preferably Poloxamer188, Poloxamer338, Poloxamer 407.
In the cannabidiol-containing composition of the invention, the antioxidant in the cannabidiol dispersed particles is a radical terminator, a metal ion chelator, or a combination of both. The free radical terminator comprises tert-Butyl Hydroxy Anisole (BHA), di-tert-Butyl Hydroxy Toluene (BHT), Propyl Gallate (PG), amyl gallate, tert-butyl hydroquinone (TBHQ), tert-butyl hydroquinone (EBHQ), polyphenol compounds (such as tea polyphenol, tocopherol, etc.), rosemary extract, lycopene, guaiac resin, riboflavin, and anthocyanin. The metal ion chelating agent is organic acid, such as citric acid, phytic acid, tartaric acid, malic acid, succinic acid, fumaric acid, maleic acid, etc.
In the cannabidiol-containing composition of the invention, the filler is a pharmaceutically acceptable filler, including mannitol, microcrystalline cellulose, lactose, pregelatinized starch 1500, corn starch, and the like.
In the cannabidiol-containing composition of the invention, the disintegrant is a pharmaceutically acceptable disintegrant, including croscarmellose sodium (CCMC-Na), corn starch, crospovidone, pregelatinized starch 1500, sodium carboxymethyl starch, and the like.
In the cannabidiol-containing composition of the invention, the lubricant is a pharmaceutically acceptable lubricant, including magnesium stearate, glyceryl stearate, sodium stearyl fumarate, stearic acid, talc, silica, and the like.
The invention also provides a preparation method of the cannabidiol hard capsule, which comprises the following steps:
1) adding cannabidiol, polyoxyethylene polyoxypropylene ether block copolymer and antioxidant into C1-3Dissolving in alcohol under stirring;
2) adding the solution obtained in the step 1) into a spray freeze dryer for spray freeze drying to prepare cannabidiol dispersed particles;
3) the cannabidiol dispersible granules, the filler, the disintegrant and the lubricant are stirred and mixed evenly, and capsules are filled according to 50 mg/capsule of cannabidiol.
Preparation of the cannabidiol hard capsule of the inventionIn the preparation method, C1-3The alcohol can be methanol, ethanol, isopropanol, and n-propanol, preferably ethanol.
In the preparation method of the cannabidiol hard capsule, the material temperature of a spray freeze dryer is set to be-45 ℃ to-20 ℃, the speed of a peristaltic pump is set to be 55 rpm to 85rpm, the drying time is set to be 6 hours to 12 hours, preferably, the material temperature is set to be-40 ℃ to-25 ℃, the speed of the peristaltic pump is set to be 60rpm to 80rpm, and the drying time is set to be 8 hours to 10 hours.
Hard gelatin capsules have their unique advantages as commonly used solid oral dosage forms: the bitter taste and the odor of the medicine which are uncomfortable can be covered, so that the medicine is neat, beautiful and easy to swallow. ② the bioavailability of the medicine is high. Capsules are different from tablets and pills, and can be prepared without adding a binder and pressure, so the capsule can be quickly disintegrated in gastrointestinal tracts, has higher effect and better absorption than pills and tablets. And thirdly, the stability of the medicine is improved. For example, the medicine sensitive to light and unstable in heat and humidity can be filled into a light-tight capsule to protect the medicine from the action of moisture, oxygen in the air and light, thereby improving the stability of the medicine.
The cannabidiol hard capsule can improve the water solubility of cannabidiol, remarkably improve in-vitro dissolution and improve bioavailability, is convenient and safe to transport, carry, store and take, does not contain harmful and irritant components, and is suitable for industrial mass production and clinical application.
Drawings
Fig. 1 is a graph showing dissolution profiles of cannabidiol hard capsules prepared in examples 4-6 of the present invention and cannabidiol hard capsules prepared in a comparative example.
Detailed Description
The following examples further illustrate the invention, but they are not to be construed as limiting or restricting the scope of the invention.
Cannabidiol used in the examples of the present invention was obtained from pharmaceutical limited of the Han union of Yunnan, and other reagents used in the examples of the present invention were commercially available conventional reagents.
Example 1 preparation of dispersed cannabidiol particles
Cannabidiol dispersed particles were prepared according to the composition of table 1.
TABLE 1
Respectively weighing 10g of CBD, 1.33g of Poloxamer33822 and 33822g of BHA, adding 450mL of ethanol, stirring to completely dissolve, setting the material temperature to-30 ℃ by using a spray freeze dryer (a laboratory spray freeze dryer YC-3000, Shanghai Yachen apparatus Co., Ltd.), setting the feed speed of a peristaltic pump to 70rpm, and setting the drying time to 8h to obtain the cannabidiol dispersed particles. The particle size of the cannabidiol dispersed particles D50 was measured to be 28 μm using a dry gas flow dispersion laser particle sizer (model HELOS-RODOS, SYMPATEC, Germany) with a dispersion pressure of 0.3 bar.
Example 2 preparation of dispersed cannabidiol particles
Cannabidiol dispersed particles were prepared according to the composition of table 2.
TABLE 2
Respectively weighing 10g of CBD, 751.9g of Poloxamer40751.9g and 0.63g of tartaric acid, adding 550mL of ethanol, stirring to completely dissolve, adopting a spray freeze dryer, setting the material temperature to be-25 ℃, setting the feed speed of a peristaltic pump to be 60rpm, and setting the drying time to be 9h to obtain the cannabidiol dispersed particles. The particle size of the cannabidiol dispersed particles D50 was measured to be 19 μm using a dry air-flow dispersion laser particle sizer with a dispersion pressure of 0.3 bar.
Example 3 preparation of dispersed cannabidiol particles
Cannabidiol dispersed particles were prepared according to the composition of table 3.
TABLE 3
Respectively weighing 10g of CBD, 30.4g of Poloxamer18830, 0.42g of citric acid and 0.83g of PGM, adding 650mL of ethanol, stirring to completely dissolve, adopting a spray freeze dryer, setting the material temperature to be-40 ℃, setting the feed speed of a peristaltic pump to be 80rpm, and setting the drying time to be 10h to obtain the cannabidiol dispersed particles. And (3) adopting a dry airflow dispersion laser particle size analyzer, setting the dispersion pressure to be 0.3bar, and determining the particle size of the cannabidiol dispersed particles D50 to be 13 mu m.
EXAMPLE 4 preparation of cannabidiol hard capsules
According to the prescription composition of table 4, 30g of cannabidiol dispersed particles, 30g of microcrystalline cellulose MCC1019.45g and crospovidone are respectively weighed
XL-100.82g, and mixing them uniformly with stirring. Finally, 0.82g of magnesium stearate SH-YM-M is weighed out and mixed. The cannabidiol is filled into capsules according to 50 mg/capsule.
TABLE 4
EXAMPLE 5 preparation of cannabidiol hard capsules
According to the prescription composition of Table 5, 60g of cannabidiol dispersed particles and mannitol are respectively weighed
Emerald 36g and CCMC-Na 3g, and stirring and mixing evenly. Finally, sodium stearyl fumarate is weighed
SSF 1g was subjected to total mixing. The cannabidiol is filled into capsules according to 50 mg/capsule.
TABLE 5
EXAMPLE 6 preparation of Cannabis diol hard capsules
According to the prescription composition of table 6, 40g of cannabidiol dispersed particles and lactose monohydrate are respectively weighed
40036g and 15003.6g of pregelatinized starch, and stirring and mixing uniformly. Finally, 0.4g of talcum powder is weighed and mixed totally. The cannabidiol is filled into capsules according to 50 mg/capsule.
TABLE 6
Preparation of comparative cannabidiol hard capsules
According to the prescription composition of Table 7, 9g of cannabidiol, 33819.8g of poloxamer, 1.2g of BHA, MCC1019.45g of microcrystalline cellulose and polyvinylpolypyrrolidone are respectively weighed
XL-100.82g, and mixing them uniformly with stirring. Finally, 0.82g of magnesium stearate SH-YM-M is weighed out and mixed. And filling the cannabidiol into capsules according to 50 mg/capsule.
TABLE 7
Test examples dissolution Curve measurement
According to the dissolution and release determination method (0931) of Chinese pharmacopoeia of 2015 edition, the second method paddle method is selected, the rotating speed is set to 75rpm, the dissolution volume is 900mL, and the dissolution medium is 0.5% Sodium Dodecyl Sulfate (SDS) aqueous solution. The dissolution curves of the samples of examples 4-6 and comparative example were measured, respectively. The results are shown in FIG. 1. As can be seen from the results of the dissolution curve measurement, compared with a comparative sample, the dissolution of the cannabidiol hard capsule prepared by adopting the technical scheme of the invention is greatly improved.
Claims (10)
1. A cannabidiol hard capsule comprising a cannabidiol-containing composition comprising, by weight, the following pharmaceutical ingredients:
2. a cannabidiol hard capsule as claimed in claim 1, wherein the cannabidiol dispersed particles comprise from 10% to 50% cannabidiol, from 50% to 88% polyoxyethylene polyoxypropylene ether block copolymer, from 0.5% to 5% antioxidant, preferably the cannabidiol dispersed particles comprise from 10% to 30% cannabidiol, from 60% to 85% polyoxyethylene polyoxypropylene ether block copolymer, from 1% to 4% antioxidant, by weight.
3. A cannabidiol hard capsule as claimed in claim 1, wherein the cannabidiol dispersed particles are spherical porous fluffy particles having a particle size D50 of from 5 to 40 μ ι η, preferably from 5 to 30 μ ι η, more preferably from 5 to 20 μ ι η, most preferably from 5 to 15 μ ι η.
4. A cannabidiol hard capsule as claimed in claim 1, wherein the weight ratio of cannabidiol to polyoxyethylene polyoxypropylene ether block copolymer in the cannabidiol dispersed particles is from 1:8 to 1:1, preferably from 1:5 to 1: 2.
5. A cannabidiol hard capsule as claimed in claim 1, wherein the weight ratio of cannabidiol to antioxidant in the cannabidiol dispersed particles is from 20:1 to 5:1, preferably from 16:1 to 7.5: 1.
6. A cannabidiol hard capsule as claimed in claim 1, wherein the polyoxyethylenepolyoxypropylene ether block copolymer in the cannabidiol dispersed particles is Poloxamer124, Poloxamer188, Poloxamer237, Poloxamer338, Poloxamer407, preferably Poloxamer188, Poloxamer338, Poloxamer 407; the antioxidant agent in the cannabidiol dispersed particles is a radical terminator, a metal ion chelator, or a combination of both.
7. A cannabidiol hard capsule as claimed in claim 6, wherein the radical terminator comprises tert-butyl hydroxyanisole, di-tert-butyl hydroxytoluene, propyl gallate, amyl gallate, tert-butyl hydroquinone, polyphenolic compounds, rosemary extract, lycopene, guaiac resin, riboflavin, anthocyanins; the metal ion chelating agent comprises citric acid, phytic acid, tartaric acid, malic acid, succinic acid, fumaric acid, and maleic acid.
8. The cannabidiol hard capsule of claim 1, wherein the filler is a pharmaceutically acceptable filler comprising mannitol, microcrystalline cellulose, lactose, pregelatinized starch 1500, corn starch; the disintegrant is medicinal disintegrant, including croscarmellose sodium, corn starch, crospovidone, pregelatinized starch 1500, and sodium carboxymethyl starch; the lubricant is a medicinal lubricant, and comprises magnesium stearate, glyceryl stearate, sodium stearyl fumarate, stearic acid, talcum powder and silicon dioxide.
9. A method for preparing cannabidiol hard capsules comprises the following steps:
1) adding cannabidiol, polyoxyethylene polyoxypropylene ether block copolymer and antioxidant into C1-3In alcohols, stirring to dissolve, wherein C1-3The alcohol is methanol, ethanol, isopropanol or n-propanol, preferably ethanol;
2) adding the solution obtained in the step 1) into a spray freeze dryer for spray freeze drying to prepare cannabidiol dispersed particles;
3) the cannabidiol dispersible granules, the filler, the disintegrant and the lubricant are stirred and mixed evenly, and capsules are filled according to 50 mg/granule of cannabidiol.
10. The method according to claim 9, wherein the material temperature of the spray freeze dryer is set to-45 ℃ to-20 ℃, the peristaltic pump speed is set to 55 to 85rpm, and the drying time is set to 6 to 12 hours, preferably, the material temperature is set to-40 ℃ to-25 ℃, the peristaltic pump speed is set to 60 to 80rpm, and the drying time is set to 8 to 10 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011443195.9A CN114601815A (en) | 2020-12-08 | 2020-12-08 | Cannabidiol hard capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011443195.9A CN114601815A (en) | 2020-12-08 | 2020-12-08 | Cannabidiol hard capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114601815A true CN114601815A (en) | 2022-06-10 |
Family
ID=81856975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011443195.9A Pending CN114601815A (en) | 2020-12-08 | 2020-12-08 | Cannabidiol hard capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601815A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101292981A (en) * | 2007-04-29 | 2008-10-29 | 杨喜鸿 | Solid dispersion, composition of rimonabant, preparation and medicament application thereof |
| US20190134121A1 (en) * | 2017-08-08 | 2019-05-09 | Steven Bermudez | Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process |
| CN110575448A (en) * | 2018-06-08 | 2019-12-17 | 云南汉素生物科技有限公司 | Cannabidiol composition and application thereof |
| CN111991355A (en) * | 2019-12-30 | 2020-11-27 | 云南汉盟制药有限公司 | Solid nanometer powder composition containing nanometer cannabidiol, preparation method and application |
-
2020
- 2020-12-08 CN CN202011443195.9A patent/CN114601815A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101292981A (en) * | 2007-04-29 | 2008-10-29 | 杨喜鸿 | Solid dispersion, composition of rimonabant, preparation and medicament application thereof |
| US20190134121A1 (en) * | 2017-08-08 | 2019-05-09 | Steven Bermudez | Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process |
| CN110575448A (en) * | 2018-06-08 | 2019-12-17 | 云南汉素生物科技有限公司 | Cannabidiol composition and application thereof |
| CN111991355A (en) * | 2019-12-30 | 2020-11-27 | 云南汉盟制药有限公司 | Solid nanometer powder composition containing nanometer cannabidiol, preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 刘元芬主编: "《高职高专"十三五"规划教材 药剂学 第2版》", 江苏科学技术出版社, pages: 168 * |
| 杨红梅: "《药剂学》", 31 July 2020, 天津科学技术出版社, pages: 27 - 28 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2560612B1 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| EP4324527A2 (en) | Formulations of enzalutamide | |
| IE60069B1 (en) | Controlled release dihydrocodeine composition | |
| EP3001811B1 (en) | Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment | |
| US20230172844A1 (en) | Cannabidiol orally disintegrating tablets | |
| CN109662949B (en) | Fluorohydrocortisone acetate orally disintegrating tablet and preparation method thereof | |
| CN104902928B (en) | Include the total micronizing product of uliprista acetate | |
| TW201311236A (en) | Celecoxib solid dispersion and its preparation method | |
| EP1707192A2 (en) | Pharmaceutical composition | |
| US20210251909A1 (en) | Taste masking drug formulations | |
| JP7470204B2 (en) | Pharmaceutical compositions, methods for their preparation and use | |
| CN114601815A (en) | Cannabidiol hard capsule and preparation method thereof | |
| US20070099996A1 (en) | Pharmaceutical compositions of acitretin | |
| KR100267525B1 (en) | Cytarabine ocfosfate hard capsule | |
| CN112336711B (en) | Glucozine lysine orally disintegrating tablet | |
| CN110664761A (en) | Lenalidomide pharmaceutical composition and preparation method thereof | |
| CN114831943B (en) | Preparation method of pharmaceutical composition | |
| WO2007049626A1 (en) | Oral solid preparation containing cabergoline | |
| JP2914690B2 (en) | Formulation containing stable vitamin D | |
| CN111588699B (en) | Pharmaceutical composition containing danazol and application thereof | |
| CN116850248B (en) | Kekeping capsule and its preparation method | |
| EP4074307A1 (en) | Formulations of cannabinoids | |
| US20240139217A1 (en) | Formulations of cannabinoids | |
| KR20200136399A (en) | Pharmaceutical Composition Containing Brexpiprazole | |
| CN117715626A (en) | Cannabinoid formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |